Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Benign prostatic hyperplasia Clinical criteria: Patient must have lower urinary tract symptoms.
“Silodosin is a selective antagonist of α 1A-adrenoreceptors primarily located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra.”
“The terminal half-life of parent drug and its glucuronide is approximately 11 hours and 18 hours, respectively.”
“Silodosin undergoes extensive metabolism through glucuronidation (UGT2B7), alcohol and aldehyde dehydrogenase and oxidative pathways, mainly CYP3A4. In vitro data indicate that silodosin does not inhibit or induce cytochrome P450 enzyme systems.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.